Exagen's Participation at ACR Convergence 2024
Exagen Inc. (NASDAQ: XGN), a renowned leader in autoimmune diagnostic solutions, has exciting news! The company announced that five of its abstracts have been accepted for presentation at the upcoming American College of Rheumatology (ACR) Convergence 2024. This prestigious annual meeting is set to take place mid-November, showcasing cutting-edge research and advancements in rheumatology.
Highlighting Innovative Research
One of the key highlights of Exagen’s contributions will be a plenary presentation developed alongside esteemed researchers from Johns Hopkins University. This presentation will feature a groundbreaking urinary biomarker panel designed to aid in the precise management of Lupus Nephritis. Such advancements are crucial for rheumatologists aiming to enhance patient outcomes.
In addition to the main presentation, Exagen will also showcase innovative findings from research focusing on novel T Cell biomarkers associated with Lupus and specific anti-RA33 autoantibodies related to rheumatoid arthritis. These findings are anticipated to greatly enhance diagnostic sensitivity for conditions assessed by the AVISE CTD platform, thereby transforming the landscape of autoimmune diagnostics.
Statements from Leadership
Expressing the company’s dedication to innovation, Dr. Andrew Concoff, Chief Innovation Officer at Exagen, remarked, “Our research highlights our commitment to pioneering new biomarkers that advance rheumatologic care. We eagerly await the opportunity to share these findings with the broader rheumatology community to enhance patient care.”
Accepted Abstracts Overview
Exagen's accepted abstracts reflect its dedication to leading advancements in autoimmune diagnostics:
Collaborative Plenary Presentation
Title: A Urinary Biomarker Panel to Predict the Probability of Histologically Active Lupus Nephritis
Presented by: Andrea Fava
Session Date and Time: Sunday, November 17, from 9:00 a.m. – 9:15 a.m. ET
Poster Presentations on Novel Biomarkers
Title: Multi-centered Clinical Validation of T Cell-bound C4d and T Cell Autoantibodies
Presented by: Vasileios Kyttaris
Session Date and Time: Sunday, November 17, from 10:30 a.m. – 12:30 p.m. ET
Title: Maximizing Diagnostic Sensitivity
Presented by: Andrew Concoff
Session Date and Time: Monday, November 18, from 10:30 a.m. – 12:30 p.m. ET
Title: Unique Biomarkers for Identifying Seronegative Rheumatoid Arthritis
Presented by: Andrew Concoff
Session Date and Time: Monday, November 18, from 10:30 a.m. – 12:30 p.m. ET
Title: Added Value of CB-CAPs in Large Validation Cohort
Presented by: Andrew Concoff
Session Date and Time: Saturday, November 16, from 10:30 a.m. – 12:30 p.m. ET
About Exagen Inc.
Exagen Inc. is at the forefront of providing diagnostic clarity to patients grappling with autoimmune diseases. With its headquarters nestled in California, the company's mission revolves around delivering accurate and timely diagnosis to improve clinical outcomes. The flagship AVISE CTD product enables healthcare providers to identify complex autoimmune conditions, such as lupus and rheumatoid arthritis, with enhanced precision. Exagen’s laboratory is known for its specialization in rheumatic diseases, offering a comprehensive suite of AVISE-branded tests that facilitate diagnosis, prognosis, and monitoring.
Through persistent research and an unwavering focus on patient-centric care, Exagen is committed to advancing the understanding and management of autoimmune diseases.
Frequently Asked Questions
What abstracts did Exagen present at ACR Convergence 2024?
Exagen presented five abstracts, including a collaboration with Johns Hopkins University focusing on a urinary biomarker panel for Lupus Nephritis.
Who is the Chief Innovation Officer at Exagen?
Dr. Andrew Concoff serves as the Chief Innovation Officer at Exagen and expresses the company's commitment to innovative research.
What is the AVISE CTD product?
AVISE CTD is Exagen's flagship diagnostic tool designed to help clinicians diagnose complex autoimmune conditions with greater accuracy.
When is the ACR Convergence 2024 meeting scheduled?
The ACR Convergence 2024 meeting will take place from November 14 to November 19.
How does Exagen contribute to rheumatology care?
Exagen provides advanced diagnostic tests that enhance the sensitivity and specificity of autoimmune disease diagnosis, aiming to improve patient care outcomes.
